Overview of the biology of type I interferons

Arthritis Research and Therapy

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Kalliolias, George D ^a   Ivashkiv, Lionel B ^a,b  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ALPHA BETA INTERFERON RECEPTOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; STAT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTHRITIS; AUTOIMMUNITY; COLITIS; IMMUNOREGULATION; INTERFERON PRODUCTION; MULTIPLE SCLEROSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; CLASSIFICATION; DISEASE MODEL; EDITORIAL; ENTERITIS; HUMAN; INFLAMMATION; METABOLISM; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VERTEBRATE; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; NEOPLASMS; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VERTEBRATES; VIRUS DISEASES;

EID: 78651414618     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2881     Document Type: Review

References (79)

1. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 2006, 25:343-348. 10.1016/j.immuni.2006.08.008, 16979566.
2. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007, 6:975-990. 10.1038/nrd2422, 18049472.
3. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381. 10.1016/j.immuni.2006.08.007, 16979569.
4. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264. 10.1146/annurev.biochem.67.1.227, 9759489.
5. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009, 86:23-32. 10.1189/jlb.1208761, 19304895.
6. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005, 5:375-386. 10.1038/nri1604, 15864272.
7. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360. 10.1016/j.immuni.2006.08.009, 16979567.
8. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002, 71:565-581.
9. Buttmann M, Rieckmann P. Interferon-β1b in multiple sclerosis. Expert Rev Neurother 2007, 7:227-239. 10.1586/14737175.7.3.227, 17341170.
10. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999, 42:90-99. 10.1002/1529-0131(199901)42:1<90::AID-ANR12>3.0.CO;2-A, 9920019.
11. Tak PP, Hart BA, Kraan MC, Jonker M, Smeets TJ, Breedveld FC. The effects of interferon beta treatment on arthritis. Rheumatology (Oxford) 1999, 38:362-369. 10.1093/rheumatology/38.4.362, 10378715.
12. van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis?. Arthritis Res 2002, 4:346-352. 153843, 12453310, 10.1186/ar598.
13. van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, Tak PP. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R239-R249. 416442, 15142270, 10.1186/ar1165.
14. Tak PP. IFN-beta in rheumatoid arthritis. Front Biosci 2004, 9:3242-3247. 10.2741/1475, 15353352.
15. Yarilina A, DiCarlo E, Ivashkiv LB. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007, 178:2204-2211.
16. Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS. Synergistic benefit in inflammatory arthritis by targeting IκB kinase epsilon and interferon beta. Ann Rheum Dis 2009, 68:257-263. 2713581, 18653628, 10.1136/ard.2008.095356.
17. Vervoordeldonk MJ, Aalbers CJ, Tak PP. Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block. Ann Rheum Dis 2009, 68:157-158. 10.1136/ard.2008.097899, 19139202.
18. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res Ther 2004, 6:R73-R77. 400417, 14979940, 10.1186/ar1026.
19. van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005, 64:64-69. 1755211, 15242865, 10.1136/ard.2003.020347.
20. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005, 115:695-702. 1051992, 15765149.
21. Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2008, 3:CD006790.
22. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392. 10.1016/j.immuni.2006.08.010, 16979570.
23. Ivashkiv LB. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003, 36:473-479. 10.1080/08916930310001605882, 14984024.
24. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336. 10.1146/annurev.immunol.23.021704.115843, 15771573.
25. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003, 36:511-518. 10.1080/08916930310001605873, 14984028.
26. Billiau A. Anti-inflammatory properties of Type I interferons. Antiviral Res 2006, 71:108-116. 10.1016/j.antiviral.2006.03.006, 16626815.
27. Biron CA. Interferons alpha and beta as immune regulators - a new look. Immunity 2001, 14:661-664. 10.1016/S1074-7613(01)00154-6, 11420036.
28. Benveniste EN, Qin H. Type I interferons as anti-inflammatory mediators. Sci Sci STKE 2007, 2007(416):pe70.
29. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543. 10.1126/science.1064890, 11711679.
30. van Holten J, Smeets TJ, Blankert P, Tak PP. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005, 64:1780-1782. 1755294, 15878901, 10.1136/ard.2005.040477.
31. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Brück W, Kalinke U. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008, 28:675-686. 10.1016/j.immuni.2008.03.011, 18424188.
32. Axtell RC, Steinman L. Type 1 interferons cool the inflamed brain. Immunity 2008, 28:600-602. 10.1016/j.immuni.2008.04.006, 18482563.
33. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008, 9:378-387. 10.1038/ni1576, 18345002.
34. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749. 10.1038/416744a, 11961557.
35. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001, 2:378-386. 10.1038/35073080, 11331912.
36. Kozyrev SV, Alarcon-Riquelme ME. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 2007, 40:591-601. 10.1080/08916930701510905, 18075793.
37. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487. 2621107, 18668568, 10.1002/art.23613.
38. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103. 10.1038/nature08512, 19890330.
39. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505. 10.1038/nature06013, 17618271.
40. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009, 138:576-591. 2747301, 19631370, 10.1016/j.cell.2009.06.015.
41. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009, 10:1065-1072. 10.1038/ni.1779, 19609254.
42. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008, 9:361-368. 10.1038/ni1569, 18297073.
43. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009, 10:1200-1207. 10.1038/ni.1792, 19801985, 2821672.
44. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E, Aozasa K, Kawai T, Akira S. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 2007, 27:240-252. 10.1016/j.immuni.2007.07.013, 17723216.
45. Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E, van Rooijen N, Moldawer L, Satoh M, Reeves WH. A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008, 180:5101-5108. 2909121, 18354236.
46. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008, 226:41-56. 2630590, 19161415, 10.1111/j.1600-065X.2008.00707.x.
47. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372. 10.1016/j.immuni.2006.08.014, 16979568.
48. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009, 31:491-501. 10.1016/j.immuni.2009.07.005, 19733096.
49. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470. 10.1016/S1074-7613(01)00126-1, 11336691.
50. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234. 10.1016/S1074-7613(03)00208-5, 12932356.
51. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006, 176:2074-2078.
52. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
53. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490. 10.1080/08916930310001625952, 14984025.
54. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 2193846, 12642603, 10.1084/jem.20021553.
55. Ramanujam M, Kahn P, Huang W, Tao H, Madaio MP, Factor SM, Davidson A. Interferon-alpha treatment of female (NZW × BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 2009, 60:1096-1101. 2703814, 19333924, 10.1002/art.24414.
56. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 2004, 172:6476-6481.
57. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, Woods JM, Haines GK, Ivashkiv LB. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol 2002, 3:859-866. 10.1038/ni828, 12172544.
58. Triantafyllopoulou A, Franzke C, Seshan S, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Nalt Acad Sci USA 2010, 107:3012-3017.
59. Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 2009, 183:6831-6838. 10.4049/jimmunol.0900742, 19864599, 2876821.
60. van Baarsen LG, Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006, 7:522-531. 10.1038/sj.gene.6364324, 16837931.
61. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132(Pt 12):3353-3365. 10.1093/brain/awp228, 19741051.
62. Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007, 66:1008-1014. 10.1136/ard.2006.063412, 17223656, 1954704.
63. Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP. Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J Gen Virol 2007, 88(Pt 6):1717-1721. 10.1099/vir.0.82603-0, 17485531, 2884954.
64. Adriaansen J, Kuhlman RR, van Holten J, Kaynor C, Vervoordeldonk MJ, Tak PP. Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum Gene Ther 2006, 17:985-996. 10.1089/hum.2006.17.985, 16984225.
65. Treschow AP, Teige I, Nandakumar KS, Holmdahl R, Issazadeh-Navikas S. Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum 2005, 52:3739-3748. 10.1002/art.21496, 16320324.
66. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008, 118:1680-1690. 2276397, 18382764, 10.1172/JCI33342.
67. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008, 29:68-78. 2625293, 18619869, 10.1016/j.immuni.2008.05.008.
68. Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006, 203:1891-1901. 2118370, 16831897, 10.1084/jem.20051725.
69. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007, 131:1124-1136. 10.1016/j.cell.2007.10.034, 18083102.
70. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Muller M, Blackshear PJ, Kovarik P. Interferons limit inflammatory responses by induction of tristetraprolin. Blood 2006, 107:4790-4797. 10.1182/blood-2005-07-3058, 16514065.
71. Hu X, Ho HH, Lou O, Hidaka C, Ivashkiv LB. Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J Immunol 2005, 175:131-138.
72. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D. The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 2005, 174:2974-2980.
73. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132. 10.1038/ni1254, 16200070.
74. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-β1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 2009, 182:3928-3936. 10.4049/jimmunol.0802226, 19265172.
75. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009, 183:5418-5427. 10.4049/jimmunol.0803227, 19783688.
76. Indraccolo S, Pfeffer U, Minuzzo S, Esposito G, Roni V, Mandruzzato S, Ferrari N, Anfosso L, Dell'Eva R, Noonan DM, Chieco-Bianchi L, Albini A, Amadori A. Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 2007, 178:1122-1135.
77. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915. 2018671, 17638846, 10.1182/blood-2007-05-089086.
78. Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB. Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat Immunol 2004, 5:1181-1189. 10.1038/ni1126, 15467722.
79. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O'Shea JJ, Biron CA. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002, 297:2063-2066. 10.1126/science.1074900, 12242445.